Market Forecast 2014-2024: Asthma and COPD Therapies


MD Spiro prides itself on not only offering incredible spirometry products for your practice, but also prides itself on providing articles and industry updates for our customers.  Below is a new study showing you trends, R&D progress, and predicted revenues in and Therapies.

So where’s the asthma and COPD therapies heading? Visiongain’s brand new report shows you potential revenues to 2024, assessing data, trends, opportunities and prospects there.

This 335-page report provides 264 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. This new study lets you assess forecasted sales at overall world market and national level. You will see financial results, interviews, trends, opportunities, and revenue predictions. Much opportunity remains in this growing pharma market.

Forecasts from 2014-2024 and other analyses show you commercial prospects

Besides revenue forecasting to 2024, our new study provides you with recent results, growth rates, and market shares. There you find original analyses, with business outlooks and developments. Discover qualitative analyses (including SWOT and Porter’s Five Forces Analysis), company profiles and commercial developments. Read the full transcripts of six exclusive expert opinion interviews from industry specialists informing your understanding and allowing you to assess prospects for investments and sales, including:

–          Clive Page, Professor of Pharmacology, King’s College London

–          Monica Fletcher, Chief Executive, Education for Health

–          Daphne Tsitoura, Senior Medical Director, GSK

–          Barbara Yawn, Director of Research, Olmsted Medical Center

–          Ahmed Wagih, Product Manager, Respiratory Franchise, GSK


Discover sales predictions for the world market and submarkets

Along with revenue prediction for the overall world market, you see forecasts to 2024 for the following submarkets:

–          Bronchodilator monotherapy – SABAs, LABAs, anticholinergic drugs

–          Anti-inflammatory drugs – inhaled corticosteroids, anti-leukotrienes, monoclonal antibodies

–          Combination drugs.

Our investigation discusses what stimulates and restrains business. You find dynamics of the industry and assess its potential sales, seeing agents likely to achieve the most success.

See revenue forecasts for products

How will leading drugs and promising products currently in development perform to 2024 at world level? Our study forecasts sales of 27 products, including these:

–          Advair/Seretide

–          Atrovent

–          Combivent

–          Flixotide/Flovent

–          Pulmicort

–          Singulair

–          Spiriva

–          Symbicort

–          Ventolin

–          Xolair

–          Reslizumab

–          Mepolizumab


Discover how high revenues can go. You see what’s happening, understanding trends, challenges and opportunities.  Our analysis also breaks the main world forecast into geographical markets.


What are the prospects in the leading regions and countries?

In addition to analyses of the overall world market, you discover individual revenue forecasts for 12 national markets to 2024:

–              US

–              Japan

–              China

–              Germany

–              France

–              UK

–              Italy

–              Spain

–              India

–              Brazil

–              Russia

–              Mexico

–              Rest of the World


There will be growth in established pharma markets and in developing countries. Our analyses show that India, Russia, China and Mexico, in particular, will continue to achieve high revenue growth to 2024. Developments worldwide in product approval and pricing will influence the market.

Leading companies and potential for market growth

Overall world revenue for asthma and COPD therapies will reach $33.1bn in 2014, our work forecasts. We predict slow revenue growth from 2014 to 2018 and faster growth from 2018 to 2024. Rising demand for asthma and COPD drugs, expanding healthcare coverage, new drugs for severe asthma and a strong R&D pipeline will increase sales to 2024.

To purchase the full report:



Leave a Reply